Comparative study of the efficacy of nano-tacrolimus and cyclosporine eye drops in patients with dry eye

Session Details

Session Title: Presented Poster Session: Spotlight on Cornea

Venue: Poster Village: Pod 2

First Author: : M.Nikandish IRAN

Co Author(s): :    M. Hanafi-Bojd                       

Abstract Details

Purpose:

To evaluate the efficacy of topical nano- tacrolimus 0.05% versus topical cyclosporine 0.05% in patients with dry eye.

Setting:

Department of Ophthalmology, Valiasr Hospital, Birjand, Iran.

Methods:

This clinical trial was conducted in 40 patients with dry eye. They were divided randomly into two groups of 40 eyes. In group I, cyclosporine 0.05% eye drops were administered while group II received 0.05% nano-tacrolimus eye drops, twice daily for 4 weeks. Complete ophthalmic examinations including Schirmer test, tear break up time (TBUT), Strip Meniscometry Tube (SMTube), fluorescein ocular surface staining and Ocular Surface Disease Index (OSDI) questionnaire were performed at first and 4 weeks following treatment. Data were entered into SPSS software and analyzed at a significant level of less than 0.05.

Results:

The mean age of the participants was 51/11±10/73. Schirmer test, TBUT, SMTube, and OSDI scores showed significant differences before and 4 weeks after treatment in group 1 (8.72±5.77 vs 9.34±8.36, p=0.02; 5.63±3.46 vs 7.94±3.10, p<0.001; 4.72±4.17 vs 6.38±4.73, p=0.003; 29.52±8.57 vs 19.83±8.93, p<0.001; respectively) and group 2 (8.12±5.16 vs 12.14±10.58, p<0.001; 5.91±3.23 vs 7.94±3.22, p<0.001; 4.69±4.06 vs 6.41±4.43, p=0.004; 29.05±8.22 vs 19.72±9.03, p<0.001; respectively). These examinations were not significantly different between two groups.

Conclusions:

Topical nano- tacrolimus has a similar efficacy and a better compliance than cyclosporine in treatment of dry eye.

Financial Disclosure:

None